Noel Chan

Assistant Professor

McMaster University

Canada

Research Interests

Explore related searches

Professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Noel Chan serves as an Assistant Professor at McMaster University in Canada. His research primarily focuses on vascular medicine, with recent publications examining the use of colchicine for secondary prevention of vascular events and the implications of anticoagulant therapies in various clinical contexts. Additionally, he has contributed to discussions surrounding drug concentrations in atrial fibrillation treatments and the relationship between human papilloma virus and cardiovascular disease.

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (6)

Kerstin de Wit

Associate Professor

Queen's University

CANADA

View details

Pedro Dantas

Head of the Hip & Pelvis Unit

PORTUGAL

View details

Shirley Jansen

University of Western Australia

AUSTRALIA

View details

Mahmoud Hafez

Honorary Visiting Professor

Cardiff University Cardiff School of Engineering

UNITED KINGDOM

View details

Charley Budgeon

University of Western Australia

AUSTRALIA

View details

R. J. Hinchliffe

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Noel Chan

Research Interests

Explore related searches

Contact this professor

About

Articles (17)

Low Dose Colchicine in Patients with Peripheral Artery Disease to Address Residual Vascular Risk (LEADER-PAD) Trial: Relevance and Importance of a Global Initiative

Colchicine for secondary prevention of vascular events: a meta-analysis of trials

Editorial Commentary to Reticulocyte Production Index in Heart Failure: Refining Prognosis Beyond Current Risk Markers?

Usual On-therapy Ranges of Drug Concentrations in Patients with Atrial Fibrillation Treated with Direct Oral Anticoagulants: A Systematic Review and Meta-analysis

Anticoagulants: From chance discovery to structure-based design

Human papilloma virus and atherosclerotic cardiovascular disease

Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events

Assessing Limb Outcomes in Drug Trials in Peripheral Artery Disease: The Need for a Universal and Pragmatic Definition

Clinical Studies with Anticoagulants that Have Changed Clinical Practice

Impact of Rabeprazole on APO-Dabigatran Exposure in Healthy Volunteers

Comparison of YEARS and Adjust-Unlikely D-dimer Testing for Pulmonary Embolism in the Emergency Department.

Thromboprophylaxis After Hip or Knee Arthroplasty.

No apparent association between mRNA COVID-19 vaccination and venous thromboembolism.

Letter by de Vries et al Regarding Article "Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis".

Management of a Left Atrial Appendage Thrombus Due to Atrial Fibrillation Complicating Québec Platelet Disorder.

Recommendations from the ICM-VTE: General.

The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges.

Collaborators (6)

Kerstin de Wit

Pedro Dantas

Shirley Jansen

Mahmoud Hafez

Charley Budgeon

R. J. Hinchliffe

Make your next move.